Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FDM19
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,899
Award facts
- Contract value 100% obligated
- $98,898.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $98.9M delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The contract, executed on September 23, 2025, is structured as a firm fixed-price delivery order with an ultimate completion date of October 15, 2025, and carries no set-aside designation. This award represents a task order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA, valued at $500M and valid through November 2026, which authorizes the agency to procure an extensive portfolio of pharmaceutical products supporting military health facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its status as a woman-owned small business to compete effectively in government procurement. The company's comprehensive offerings encompass branded and generic prescription drugs, biologics, over-the-counter medications, and specialty pharmaceutical products, with demonstrated capability in delivering complex pharmaceutical items such as oncology treatments, vaccines, and injectable medications to Department of Defense healthcare sites. This delivery order for Entyvio, a biologic immunosuppressant medication, aligns with the company's established track record of providing high-value pharmaceutical products to federal agencies.
Quick answers
Who was awarded contract SPE2DB25FDM19?
SPE2DB25FDM19 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 23, 2025.
How much is contract SPE2DB25FDM19 worth?
The government has obligated $98,899 on SPE2DB25FDM19.
Is contract SPE2DB25FDM19 an order under another contract?
Yes. SPE2DB25FDM19 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDM19 competed?
The extent of competition for SPE2DB25FDM19 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award